Butrans Patch, Extended Release
Product Images NDC 59011-751

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 31 technical images submitted to the FDA as part of the official labeling for Butrans (NDC 59011-751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Knoa Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

302919 0c 5 Mcg Pouch

302919 0c 5 Mcg Pouch
FDA Label Image

302920 0c 10 Mcg Pouch

302920 0c 10 Mcg Pouch
FDA Label Image

302921 0c 20 Mcg Pouch

302921 0c 20 Mcg Pouch
This appears to be a product description for "Butrans Transdermal System," a medication containing buprenorphine used for the treatment of pain. The pack contains 5 patches, and each patch contains 20g of the active ingredient. The medication is administered through a transdermal system which is to be applied every 8 to 16 hours, and caution should be taken to keep the product out of reach of children. The text includes some potentially misspelled words due to errors.*
FDA Label Image

302922 0d 5 Mcg Carton

302922 0d 5 Mcg Carton
FDA Label Image

302923 0d 10 Mcg Carton

302923 0d 10 Mcg Carton
FDA Label Image

302924 0d 20 Mcg Carton

302924 0d 20 Mcg Carton
FDA Label Image

30300 0c 15 Mcg Pouch

30300 0c 15 Mcg Pouch
FDA Label Image

303301 0d 15 Mcg Carton

303301 0d 15 Mcg Carton
FDA Label Image

303368 0b 7.5 Mcg Pouch

303368 0b 7.5 Mcg Pouch
FDA Label Image

303369 0c 7.5 Mcg Carton

303369 0c 7.5 Mcg Carton
FDA Label Image

Figure A Instructions (Butrans Instr Figa)

Figure A Instructions (Butrans Instr Figa)
FDA Label Image

Figure B Instructions (Butrans Instr Figb)

Figure B Instructions (Butrans Instr Figb)
FDA Label Image

Figure C Instructions (Butrans Instr Figc)

Figure C Instructions (Butrans Instr Figc)
FDA Label Image

Figure D Instructions (Butrans Instr Figd)

Figure D Instructions (Butrans Instr Figd)
FDA Label Image

Figure E Instructions (Butrans Instr Fige)

Figure E Instructions (Butrans Instr Fige)
FDA Label Image

Figure F Instructions (Butrans Instr Figf)

Figure F Instructions (Butrans Instr Figf)
FDA Label Image

Figure G Instructions (Butrans Instr Figg)

Figure G Instructions (Butrans Instr Figg)
FDA Label Image

Figure H Instructions (Butrans Instr Figh)

Figure H Instructions (Butrans Instr Figh)
FDA Label Image

Figure I Instructions (Butrans Instr Figi)

Figure I Instructions (Butrans Instr Figi)
FDA Label Image

Figure J Instructions (Butrans Instr Figj)

Figure J Instructions (Butrans Instr Figj)
FDA Label Image

Figure K Instructions (Butrans Instr Figk)

Figure K Instructions (Butrans Instr Figk)
FDA Label Image

Figure L Instructions (Butrans Instr Figl)

Figure L Instructions (Butrans Instr Figl)
FDA Label Image

Figure M Instructions (Butrans Instr Figm)

Figure M Instructions (Butrans Instr Figm)
FDA Label Image

Figure N Instructions (Butrans Instr Fign)

Figure N Instructions (Butrans Instr Fign)
FDA Label Image

Figure O Instructions (Butrans Instr Figo)

Figure O Instructions (Butrans Instr Figo)
FDA Label Image

Butrans-structure (Butrans Structure)

Butrans-structure (Butrans Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This appears to be a description of a layered product used for drug delivery. The product consists of five layers - the backing layer, overlapping adhesive film, separating layer, drug/polymer adhesive matrix, and a peel-off release liner. The specific purpose and application of this product is not clear from the given text.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
This is a chart displaying the concentration (in pg/mL) of o-Butrans over time (in days) for a group of 36 individuals who received a 10mg/hour dosage once every 7 days for 3 weeks. It also shows the removal of Butrans over time.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
This is a graph representing the percentage of patients improved in a medical trial. The X-axis represents the percentage of reduction/improvement in pain, ranging from 0% to 280%. The Y-axis represents the percentage of patients improved, ranging from 0% to 100%. The trial compares a placebo group with a drug called Bulrans 10720. It appears that the drug had a higher percentage of patients improved compared to the placebo, as shown by the graph.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This seems to be a chart or a graph showing the percentage of patients who improved their pain after using a medication called "Butrans20". The chart goes from 0% to 100% in increments of 10%. However, there is no clear indication of what axis the improvement percentages are listed on.*
FDA Label Image

Table-1 (Table 1)

Table-1 (Table 1)
This appears to be part of a medical chart or prescription record. It mentions a previous opioid analgesic and the daily dose in terms of morphine equivalent. It also recommends a medication called Butrans and mentions a starting dose. Without additional context, it is difficult to provide a more specific description.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.